ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0176

Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

(0176–0195) Healthcare Disparities in Rheumatology Poster I: Lupus

9:00AM-11:00AM: Abstract Number: 0587

Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data

(0582–0608) SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0530

Impact of Upadacitinib on Wearable Device-Measured Physical Activity in Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Trial

(0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I

9:00AM-11:00AM: Abstract Number: 0149

Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study

(0145–0154) Epidemiology & Public Health – Interprofessional Poster

9:00AM-11:00AM: Abstract Number: 0233

Impaired Anti-oxidant Function of HDL and Its Associated Protein, Paraoxonase-1, in Patients with Gout

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0091

Impaired X-Chromosome Inactivation Maintenance in T Cells Is Associated with Features of Reduced Disease Severity in a Toll-Like Receptor 7-Driven Model of Systemic Autoimmunity

(0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 0310

Implementing an Osteoarthritis Management Program to Deliver Guideline-Driven Care for Knee and Hip Osteoarthritis in a U.S. Academic Health System

(0308–0324) Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 0123

Improving Interpretation of Work Outcomes in Patients with Inflammatory Rheumatic Musculoskeletal Disease: General Population Reference Curves for Work Ability and At-work Productivity

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0198

Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0248

In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0141

In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0239

Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0648

Incidence and Prevalence of Malnutrition and Its Impact on Mortality in the Multicentre Singapore Systemic Sclerosis Cohort

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0120

Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0218

Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases

(0196–0228) Infection-related Rheumatic Disease Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.